Vitamin D Receptor Activators and Clinical Outcomes in Chronic Kidney Disease

Table 11

Renal protection and inhibition of the rennin-angiotensin system.

Author	Year	Study	Outcome
Freundlich et al. [47]	2008	Study in remnant kidney model of chronic renal failure (5/6 nephrectomy) mice, administrating two different doses of paricalcitol thrice weekly for 8 weeks.	Paricalcitol was found to decrease angiotensinogen, renin, renin receptor, and vascular endothelial growth factor mRNA levels in the remnant kidney by 30–50% compared to untreated animals.
Bodyak et al. [37]	2007	Study in Dahl salt-sensitive (DSS) rats. Evaluation of the ability of paricalcitol to attenuate the development of LV abnormalities.	Paricalcitol significantly reduced cardiac renin expression in DSS rats